An observational study in Hematological Malignancy and Solid Tumor Malignancy, sponsored by Century Therapeutics, Inc.. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by Century Therapeutics, Inc. · Observational
This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.
1,464 studies on the registry are indexed under Hematologic Neoplasms; 433 are open to participants now.
This study's planned enrollment of 375 is above the median of 186 across 326 observational studies indexed under Hematologic Neoplasms.
Browse Hematologic Neoplasms studies →Century Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants who have been previously treated with cellular therapy products in an eligible investigational index trial.
Exclusion Criteria:
-This study has no exclusion criteria.
Participants who have previously received an induced pluripotent stem cell (iPSC)-derived, ex vivo genome edited cellular therapy product in an eligible Century-sponsored index trial will be enrolled in this study for up to 180 months following the last treatment with a cellular therapy product in an eligible index trial.
Other: No Intervention
As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
Number of Participants With any Adverse Events of Special Interest (AESI)
Time frame: Up to 180 months
Number of Participants With Cellular Product-related Serious Adverse Events (SAEs)
Time frame: Up to 180 months
Overall Survival (OS)
OS is defined as the time from first treatment with a cellular therapy product in the index trial to date of death by any cause.
Time frame: From first dose of study drug up to end of the study or death whichever occurs first (up to 180 months)
Percentage of Participants With Persistent Product
Persistence of the cellular product will be assessed by a droplet digital polymerase chain reaction molecular test to evaluate transgene copies in the peripheral blood. Summary of persistence sample results (positive/negative) will be reported.
Time frame: Up to 180 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.